Orthocell Limited (ASX:OCC) Gains Thai FDA Approval for Remplir™
Orthocell (ASX:OCC) receives Thai FDA approval to launch Remplir™, expanding into the US$84 million nerve repair market.
Category: Companies
Lynas Rare Earths Ltd (ASX:LYC) Announces Q3 FY25 Quarterly Report
Lynas Rare Earths Ltd (ASX:LYC) reports Q1 FY25 sales revenue of A$123m and initiates production of Dysprosium, reinforcing its strategic position in the rare earths market.
ResMed Inc. (ASX:RMD) Reports Q1 2025 Financial Results
ResMed Inc. (ASX:RMD) reports Q1 2025 revenues up 8% and diluted EPS of $2.48, declaring a $0.53 dividend per share.
Eagle Mountain Mining (ASX:EM2) Completes Rights Issue
Eagle Mountain Mining (ASX:EM2) completes rights issue, raising A$5.9 million and advancing key projects.
Surefire Resources NL (ASX:SRN) Announces Q1 2025 Highlights
Surefire Resources NL (ASX:SRN) extends Yidby gold mineralisation, advances copper systems, secures offtake agreement, and receives R&D rebate.
Future Battery Minerals (ASX:FBM) Identifies Key Gold Targets and Expands WA Landholdings
Future Battery Minerals (ASX:FBM) announces key gold targets at Kal North and expands Western Australia landholdings, enhancing exploration prospects.
Australian Rare Earths Limited (ASX:AR3) Completes EL6678 Farm-In
Australian Rare Earths Limited (ASX:AR3) finalises farm-in agreement for EL6678, expanding its Overland Uranium Project with promising exploration results.
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
Hot Chili Limited (ASX:HCH) Announces Costa Fuego PFS and Maiden Ore Reserve
Hot Chili Limited (ASX:HCH) releases the Costa Fuego PFS and maiden ore reserve, highlighting robust financials and significant exploration advancements.
Cynata Therapeutics Limited (ASX:CYP) Releases Q1 2025 Activity Report
Cynata Therapeutics (ASX:CYP) reports progress in key clinical trials and maintains a strong financial position in Q1 2025.